Investing in small biotech stocks is terribly risky, but once in a while a few stocks produce astounding gains. An $8,000 investment in AxoGen10 years ago, for example, would be worth about $258,400 today.
The biggest long-term biotech winner of the past decade, though, is Pfizer’s latest splurge, Medivation. Eight grand invested in the developer of prostate cancer therapy Xtandi would be worth about $620,800 today.
Let’s look at what’s caused these stocks to put up outstanding gains, and measure their chances of further success.
